“… Perez-Balbuena et al 2016 47 | Randomized, double-masked, multi-center study | Xanthan gum 0.09% and chondroitin sulfate 0.1% PEG 400 0.4% and PG 0.3% | N = 76 N = 72 | 49.9 ± 16.0 45.5 ± 12.7 | 2 months (4x/day) | None | Schirmer’s, TBUT, Symptoms, Corneal & conjunctival staining | Schirmer’s, TBUT, Symptoms | Corneal & conjunctival staining | Clinical Trial NCT01657253 Cochrane Risk of Bias R+C?M+O?I+S+B+ |
Pinto-Bonilla et 2015 42 | Randomized, open-label, crossover, single-center study | Trehalose and SH 1.5mg/mL -Thealoz Duo PEG & HP-guar - Systane | N = 9 N = 8 | 45.3 ± 11.8 53.8 ± 14.6 | 1 week (5x/day) (Actual 3.7±0.9 / 3.5±0.9) | None | Symptoms, Corneal & conjunctival staining, Schirmer’s, TBUT | Symptoms | Schirmer’s TBUT, Corneal & conjunctival staining | CLINICAL TRIAL NOT REGISTERED |
Postorino et al 2018 53 | Randomized, investigator-masked, single-center study | HA crosslinked + CoQ10 HA 0.15% crosslinked | N = 20 N = 20 | 60.2 ± 13.6 60.9 ± 12.5 | 3 months (4x/day) | Symptoms, MGD assessment, corneal / conjunctival staining, epithelial hyperreflectivity and keratocytes with HA + CoQ10 | Symptoms, corneal aesthesiometry TBUT | OSDI MGD assessment, corneal / conjunctival staining, epithelial hyperreflectivity and keratocytes with HA + CoQ10 only | Corneal aesthesiometry TBUT | Fluorescein staining only Clinical Trial NCT03074344 - meibomian gland assessment and confocal additionally reported Cochrane Risk of Bias R+C+M-O?I?S-B? |
Pult et al 2021 77 | Randomized, double-masked, crossover, multi-center study | Phospholipid 0.98% - Tears Again Phospholipid 0.12% - Ocuvers | N=30 (all treatments) | 33.2±1.8 | |
…”